News – Page 1132 – Endpoints News

Behind the scenes of J&J’s $30B Actelion buyout: Walkouts, Sanofi’s blunder and a $230M sweetener

9 years ago

PhRMA disses Marathon CEO—and PhRMA board member—Jeff Aronin after latest price gouging controversy

9 years ago

Valeant gets an FDA OK for new psoriasis drug brodalumab — but there’s a big catch

9 years ago

Patent board tells CRISPR scientists to back off from a nasty fight over gene editing tech

9 years ago

Ionis bags a $75M milestone from Bayer; Inventiva garners $51M from IPO

9 years ago

No, President Trump, biopharma does not want you to deregulate drug development

9 years ago

Versant gambles $20 million on a UCSD spinout focused on NASH and fibrosis

9 years ago

Surrozen grabs $33M, joins startups looking to spark a comeback in regenerative med

9 years ago

Ardelyx touts a PhIII hyperphosphatemia success for tenapanor, looking to calm fears over diarrhea

9 years ago

Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII

9 years ago

Merck’s leading PhIII BACE drug implodes in latest Alzheimer’s disaster

9 years ago

The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump

9 years ago

Martin Shkreli continues college tour with stops at Harvard, UMass; Vernalis picks up $3M milestone

9 years ago

Celgene co-founder Sol Barer bags a Johns Hopkins immuno-oncology spinout in buyout

9 years ago

Agenus pockets a fast $80M in cash and hands the R&D keys over to Incyte

9 years ago

Gilead proves it's one tough contender in HIV, but don't count GSK out of the fight

9 years ago

Aviragen Therapeutics slammed again by its second trial failure in days, this time for their lead drug

9 years ago

Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price

9 years ago

On a shopping spree, Allergan bags CoolSculpting tech in $2.5B buyout; Akebia strikes research deal with J&J

9 years ago

Sage shares get a bump from a snapshot of new PhII depression data

9 years ago

Zosano shares soar as its pivotal migraine drug patch study comes through

9 years ago

Activists slam Immunomedics’ $2B deal with Seattle Genetics in the middle of a proxy war

9 years ago

Axovant races to PhIII dementia study as nelotanserin clears an early hurdle, but questions linger

9 years ago

The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price

9 years ago

First page Previous page 1129 1130 113111321133 1134 1135 Next page Last page